GlassScriptPhysician profile
Charles H Davis
NPI 1346268810
$7,135.15
in general payments reported to CMS, 2019-2025
47 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $787 · 2021: $1,163 · 2022: $817 · 2023: $881 · 2024: $1,647 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,146 · Consulting Fee: $400 · Entertainment: $13.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,146.21 |
| Consulting Fee | $400.00 |
| Entertainment | $13.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,037.91 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Pfizer INC. | $649.51 | 2019-2025 | |
| Astellas Pharma US INC | $622.51 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $529.94 | 2024-2025 | Gemtesa |
| Lilly USA, LLC | $487.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $485.75 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $478.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $389.40 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $307.09 | 2020-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.74 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $176.95 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $143.77 | 2019-2025 | |
| Eisai INC. | $143.37 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $118.43 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $102.74 | 2021-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.